Es gab 50 kürzliche Insider-Transaktionen für Unicycive Therapeutics, Inc. (UNCY), darunter 36 Käufe und 11 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $12.66M und die gesamten Insider-Verkäufe auf $184.61K.
Bedeutende Insider mit kürzlicher Aktivität umfassen Aggarwal Gaurav, Townsend John, Laumas Sandeep. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — UNCY
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2025-08-25 |
Aggarwal Gaurav |
Director |
Aktienrückgabe |
3,199 |
$4.90 |
$15.68K |
- |
| 2025-07-28 |
Townsend John |
Chief Financial Officer |
RSU-Zuteilung |
10,000 |
$4.71 |
$47.1K |
101,557 |
| 2025-07-28 |
Aggarwal Gaurav |
Director |
RSU-Zuteilung |
21,200 |
$4.71 |
$99.85K |
39,200 |
| 2025-07-28 |
Laumas Sandeep |
Director |
RSU-Zuteilung |
21,200 |
$4.71 |
$99.85K |
41,286 |
| 2025-07-28 |
Gupta Pramod |
EVP, Pharmaceuticals and Bd |
RSU-Zuteilung |
90,000 |
$4.71 |
$423.9K |
301,986 |
| 2025-07-28 |
Gupta Shalabh K. |
CEO |
RSU-Zuteilung |
325,000 |
$4.71 |
$1.53M |
968,951 |
| 2025-07-28 |
Kenkare-mitra Sara |
Director |
RSU-Zuteilung |
21,200 |
$4.71 |
$99.85K |
39,200 |
| 2025-07-28 |
Jermasek Douglas |
EVP of Corporate Strategy |
RSU-Zuteilung |
10,000 |
$4.71 |
$47.1K |
215,500 |
| 2025-02-18 |
Aggarwal Gaurav |
Director |
Aktienrückgabe |
686 |
$0.49 |
$336.14 |
3,119 |
| 2024-10-09 |
Aggarwal Gaurav |
Director |
Aktienrückgabe |
2,695 |
$0.49 |
$1.32K |
3,885 |
| 2024-08-12 |
Townsend John |
Chief Financial Officer |
RSU-Zuteilung |
40,256 |
$0.34 |
$13.69K |
915,565 |
| 2024-08-12 |
Gupta Pramod |
EVP, Pharmaceuticals and Bd |
RSU-Zuteilung |
81,750 |
$0.34 |
$27.8K |
2,119,862 |
| 2024-08-12 |
Gupta Shalabh K. |
CEO |
RSU-Zuteilung |
232,868 |
$0.34 |
$79.18K |
6,439,505 |
| 2024-08-12 |
Jermasek Douglas |
EVP of Corporate Strategy |
RSU-Zuteilung |
81,750 |
$0.34 |
$27.8K |
2,055,000 |
| 2024-04-15 |
Townsend John |
Chief Financial Officer |
RSU-Zuteilung |
228,119 |
$1.14 |
$260.06K |
875,309 |
| 2024-04-15 |
Gupta Pramod |
EVP, Pharmaceuticals and Bd |
RSU-Zuteilung |
463,250 |
$1.14 |
$528.11K |
2,038,112 |
| 2024-04-15 |
Gupta Shalabh K. |
10 Percent Owner, Officer: CEO |
RSU-Zuteilung |
1,319,583 |
$1.14 |
$1.5M |
6,206,637 |
| 2024-04-15 |
Jermasek Douglas |
EVP of Corporate Strategy |
RSU-Zuteilung |
463,250 |
$1.14 |
$528.11K |
1,973,250 |
| 2023-09-05 |
Aggarwal Gaurav |
Director |
RSU-Zuteilung |
180,000 |
$0.76 |
$136.8K |
180,000 |
| 2023-09-05 |
Ryan John L |
Director |
RSU-Zuteilung |
112,147 |
$0.76 |
$85.23K |
123,775 |
| 2023-09-05 |
Laumas Sandeep |
Director |
RSU-Zuteilung |
189,236 |
$0.76 |
$143.82K |
200,864 |
| 2023-09-05 |
Kenkare-mitra Sara |
Director |
Unbekannt |
- |
- |
- |
- |
| 2023-09-05 |
Kenkare-mitra Sara |
Director |
RSU-Zuteilung |
180,000 |
$0.76 |
$136.8K |
180,000 |
| 2023-08-28 |
Townsend John |
Chief Financial Officer |
RSU-Zuteilung |
570,329 |
$0.75 |
$427.75K |
647,190 |
| 2023-08-28 |
Gupta Pramod |
EVP, Pharmaceuticals and Bd |
RSU-Zuteilung |
1,355,000 |
$0.75 |
$1.02M |
1,574,862 |
| 2023-08-28 |
Gupta Shalabh K. |
CEO |
RSU-Zuteilung |
4,684,775 |
$0.75 |
$3.51M |
4,988,798 |
| 2023-08-28 |
Jermasek Douglas |
EVP of Corporate Strategy |
RSU-Zuteilung |
1,355,000 |
$0.75 |
$1.02M |
1,510,000 |
| 2023-07-11 |
Aggarwal Gaurav |
Director |
Umwandlung (Verkauf) |
8,077 |
$0.49 |
$3.96K |
- |
| 2023-07-11 |
Gupta Pramod |
EVP, Pharmaceuticals and Bd |
Optionsausübung (Verkauf) |
20 |
$0.49 |
$9.80 |
- |
| 2023-07-11 |
Gupta Shalabh K. |
CEO |
Optionsausübung (Verkauf) |
50 |
$0.49 |
$24.50 |
- |
| 2023-07-11 |
Jermasek Douglas |
EVP of Corporate Strategy |
Optionsausübung (Verkauf) |
50 |
$0.49 |
$24.50 |
- |
| 2023-03-08 |
Aggarwal Gaurav |
Director |
Unbekannt |
- |
- |
- |
- |
| 2023-03-08 |
Aggarwal Gaurav |
Director |
RSU-Zuteilung |
8,077 |
$0.49 |
$3.98K |
8,077 |
| 2023-03-08 |
Gupta Pramod |
EVP, Pharmaceuticals and Bd |
RSU-Zuteilung |
20 |
$0.49 |
$9.87 |
20 |
| 2023-03-08 |
Gupta Shalabh K. |
CEO |
RSU-Zuteilung |
50 |
$0.49 |
$24.67 |
50 |
| 2023-03-08 |
Jermasek Douglas |
EVP of Corporate Strategy |
RSU-Zuteilung |
50 |
$0.49 |
$24.67 |
50 |
| 2022-11-21 |
Townsend John |
Chief Financial Officer |
RSU-Zuteilung |
35,000 |
- |
- |
76,861 |
| 2022-11-21 |
Gupta Pramod |
EVP, Pharmaceuticals and Bd |
RSU-Zuteilung |
28,000 |
- |
- |
219,862 |
| 2022-11-21 |
Gupta Shalabh K. |
CEO |
RSU-Zuteilung |
86,000 |
- |
- |
202,279 |
| 2022-11-21 |
Jermasek Douglas |
EVP of Corporate Strategy |
RSU-Zuteilung |
55,000 |
- |
- |
155,000 |
| 2022-11-18 |
Jermasek Douglas |
Director |
Veräußerung |
- |
- |
- |
70,400 |
| 2022-07-15 |
Schiller Brigitte |
Director |
Optionsausübung |
26,738 |
- |
- |
26,738 |
| 2022-07-15 |
Schiller Brigitte |
Director |
Unbekannt |
- |
- |
- |
- |
| 2022-05-16 |
Schiller Brigitte |
Director |
Informierter Kauf |
15,000 |
$0.83 |
$12.38K |
15,000 |
| 2021-07-15 |
Townsend John |
Chief Financial Officer |
RSU-Zuteilung |
18,605 |
$5.00 |
$93.03K |
41,861 |
| 2021-07-15 |
Gupta Pramod |
EVP, Pharmaceuticals and Bd |
RSU-Zuteilung |
34,884 |
$5.00 |
$174.42K |
191,862 |
| 2021-07-15 |
Gupta Shalabh K. |
CEO |
RSU-Zuteilung |
116,279 |
$5.00 |
$581.4K |
218,023 |
| 2021-07-12 |
Townsend John |
Chief Financial Officer |
Veräußerung |
23,256 |
$7.01 |
$163.02K |
- |
| 2021-07-12 |
Ryan John L |
Director |
Veräußerung |
11,628 |
$0.01 |
$116.28 |
- |
| 2021-07-12 |
Laumas Sandeep |
Director |
Veräußerung |
11,628 |
$0.01 |
$116.28 |
- |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
